Alumni raised $1.45B in 2022 - Download Free Report Now

Kolltan Pharmaceuticals

Novel monoclonal antibody therapies targeting receptor tyrosine kinases to treat cancers.

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Kolltan Pharmaceuticals plus 5521 other startups.

Start Free 7 Day Trial Now

Learn More About Kolltan Pharmaceuticals

Technology/product details

Revenue projections

Capital raised to date

Growth strategy

Competing Startups


Companies We Work With